Publications by authors named "C Hauser-Kronberger"
Alterations of the androgen receptor (AR) are associated with resistance to AR-directed therapy in prostate cancer. Thus, it is crucial to develop robust detection methods for AR alterations as predictive biomarkers to enable applicability in clinical practice. We designed and validated five multiplex droplet digital PCR assays for reliable detection of 12 AR targets including AR amplification, AR splice variant 7, and 10 AR hotspot mutations, as well as AR and KLK3 gene expression from plasma-derived cell-free DNA and cell-free RNA.
View Article and Find Full Text PDFTransferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer - Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT).
Breast Care (Basel)
February 2022
Article Synopsis
- The study investigates the feasibility and frequency of using a 70-gene signature test to guide adjuvant chemotherapy decisions for high-risk patients with HR-positive, HER2-negative early breast cancer in Austria.
- Results indicated that among the 224 patients studied, a significant portion received genomic testing, influencing treatment recommendations based on their risk classification.
- Findings suggest that the MINDACT trial's results are applicable in the Austrian context, confirming the practicality of integrating genomic testing into standard clinical practice for breast cancer treatment decisions.
Background: Bendamustine, a medication approved for the treatment of indolent non-Hodgkin lymphoma, has already shown anticancer activity in metastatic breast cancer (MBC). Here, we present the results of a phase II trial of bendamustine in combination with capecitabine in pre-treated patients with MBC.
Patients And Methods: AGMT MBC-6 is a multicentre, open-label, single-arm phase II study in HER2-negative MBC.
Incremental Impact of [ Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.
Mol Imaging Biol
February 2022
Purpose: The main objective of this prospective study was to assess the value of gallium-68 prostate-specific membrane antigen ([ Ga]Ga-PSMA-11) positron emission tomography/computed tomography (PET/CT) in primary N and M staging of intermediate- and high-risk prostate cancer (PCa) patients before planned curative-intent radical prostatectomy (RPE) and extended pelvic lymph node dissection (ePLND). The second objective was to compare the [ Ga]Ga-PSMA-11 PET/CT findings with standard of care pelvic multi-parametric magnetic resonance imaging (mpMRI) in the detection of locoregional lymph node metastases and intraprostatic prostate cancer.
Procedures: A total of 81 patients (mean age: 64.
Article Synopsis
- FOLFIRINOX is more effective than gemcitabine for treating pancreatic cancer, but it comes with higher toxicity levels and the need for biomarkers to predict patient responses.
- Certain microRNAs, specifically miR-21-5p, miR-10b-5p, and miR-34a-5p, are linked to resistance against gemcitabine, but their expression levels do not significantly impact outcomes for FOLFIRINOX treatment.
- A study involving 29 patients shows that the combination of chemotherapy in FOLFIRINOX can potentially counteract some negative prognostic factors associated with advanced pancreatic cancer.